Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Khalid Al Anezi"'
Publikováno v:
Hematology Reports, Vol 13, Iss 1 (2021)
For patients with Hodgkin Lymphoma (HL) who experience relapse post allogeneic stem cell transplantation, limited treatment options exist, and the ultimate outcome is poor. Recently, the programmed cell death protein-1 (PD-1) inhibitors have shown re
Externí odkaz:
https://doaj.org/article/2c55f0ed380e4f6599a61dbcd9afff9a
Autor:
Riad El Fakih, Mohsen Alzahrani, Abdulaziz Hamadah, Khalil Al-Farsi, Tusneem Elhassan, Mohammed F. Essa, Alfadil Haroon, Reem S. Almaghrabi, Khalid Al Anezi, Naif I. AlJohani, Panayotis Kaloyannidis, Ibraheem H. Motabi, Mouhab Ayas, Ashraf M. Suhebeh, Imran K Tailor, Ahmad Alsaeed, Ahmad Alhuraiji, Murtadha Al-Khabori, Moussab Damlaj, Mahmoud Aljurf, Bader Alahmari, Hani Al Hashmi, Syed Osman Ahmed, Sameer Alamoudi, Ibraheem Abosoudah, Feras Alfraih, Saud Alhayli
Publikováno v:
Bone Marrow Transplantation
Background: The coronavirus disease‐2019 (COVID‐19) caused by SARS Coronavirus 2 (SARS‐CoV‐2) is a potentially lethal infection. Cancer patients, and specifically hematopoietic cell transplant (HCT) recipients are severely immunocompromised a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1502f43d0b886ffb622c12323f19d39
https://doi.org/10.1038/s41409-021-01312-y
https://doi.org/10.1038/s41409-021-01312-y
Autor:
Eshrak Al Shaibani, Hani Al Hashmi, Khalid Al Anezi, John Apostolidis, Panayotis Kaloyannidis, Ahmed Buali, Taghreed Hindi, Rawan Omari, Ayed Garni, Eman Eldebawy, Heba Raslan
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e112-e119
Background and purpose: Patients with refractory or relapsed lymphoma diagnosed with bulky disease at relapse or with residual disease post salvage treatment are considered to have dismal outcome, even post autologous hematopoietic stem cell transpla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::029314b9f240c0a12371e7e7db0d4597
https://doi.org/10.1016/j.clml.2020.08.028
https://doi.org/10.1016/j.clml.2020.08.028
Autor:
Ioannis Apostolidis, Solaf Kanfar, Khalid Al Anezi, Panayotis Kaloyannidis, Eshrak Al Shaibani, Hani Al Hashmi
Publikováno v:
Bone Marrow Transplantation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe7398cac6da1bbb2f28dd86856fdbfa
https://doi.org/10.1038/s41409-018-0362-7
https://doi.org/10.1038/s41409-018-0362-7
Publikováno v:
Hematology Reports
Hematology Reports, Vol 13, Iss 1 (2021)
Hematology Reports, Vol 13, Iss 1 (2021)
For patients with Hodgkin Lymphoma (HL) who experience relapse post allogeneic stem cell transplantation, limited treatment options exist, and the ultimate outcome is poor. Recently, the programmed cell death protein-1 (PD-1) inhibitors have shown re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f7cf8e90ae6b5d8f3a38adeb8d07e52
https://doi.org/10.4081/hr.2021.8780
https://doi.org/10.4081/hr.2021.8780
Autor:
Khalid Al Anezi, Heba Raslan, Arwa Al Saber, Dina Soliman, Panayotis Kaloyannidis, Omar Abduljalil, Mahmoud M Kamel, Mohammed Al-Sayegh, Afra Al-Dayel, Ali Al Matrok, Hani Alhashmi
Publikováno v:
Health Science Journal. 12
Background: Risk stratification in Multiple Myeloma is typically done based on a set of chromosomal abnormalities including translocations and deletions and karyotype abnormalities such as hypodiploidy and hyperdiploidy. Hyperdiploidy has been consid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0fa61a85d6cd68ddac744fe51d37d92
https://doi.org/10.21767/1791-809x.1000590
https://doi.org/10.21767/1791-809x.1000590
Autor:
Infran Maghfoor, Eshrak Al Shaibani, Ioannis Apostolidis, Mohamad Darweesh, Harbi Salman, Enas Mutahar, Khalid Al Anezi, M S Rauf, Panayotis Kaloyannidis, Jenifer Bacal, Hani Al Hashmi, Tusneem Elhassan, Solaf Kafnar, Saad Akhtar
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:S187-S188
Background The ideal conditioning regimen still remains a challenge in the autologous stem cell transplantation (ASCT) setting for relapsed/refractory Hodgkin Lymphoma (RR-HL). BEAM is the most popular preparative regimen but single agent high dose M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e345f0aba41c35c08b8ab87624c4132
https://doi.org/10.1016/j.bbmt.2018.12.773
https://doi.org/10.1016/j.bbmt.2018.12.773
Autor:
Eshrak Al Shaibani, Mohamad Darweesh, Ioannis Apostolidis, Enas Mutahar, Ahmed Buali, Solaf Kafnar, Eman Debawy, Rawan Omari, Khalid Al Anezi, Panayotis Kaloyannidis, Jenifer Bacal, Reem Khalili, Hani Al Hashmi
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:S397-S398
Introduction Patients with Hodgkin (HL) or Non-Hodgkin Lymphoma (NHL) who have either bulky masses at relapse or residual disease post salvage therapy, have poor outcome even after autologous stem cell transplantation (ASCT). Involved field radiother
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::647d0b38be4653a6684e058052259cef
https://doi.org/10.1016/j.bbmt.2018.12.811
https://doi.org/10.1016/j.bbmt.2018.12.811
Autor:
Reem Khalili, Enas Mutahar, Nihad Mokhtar, John Apostolidis, Fuad Aburahma, Eshrak Al Shaibani, Khalid Al Anezi, Panayotis Kaloyannidis, Omar Abduljalil, Ann Estanislao, Hani Al Hashmi
Publikováno v:
Biology of Blood and Marrow Transplantation. 24:S143-S144
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a30e94dc4ef2646fbed3ff9b5b13a163
https://doi.org/10.1016/j.bbmt.2017.12.095
https://doi.org/10.1016/j.bbmt.2017.12.095
Autor:
Solaf Kafnar, Khalid Al Anezi, Eshrak Al Shaibani, Panayotis Kaloyannidis, Hani Al Hashmi, Jenifer Bacal, Nihad Mokhtar, Mohammed Darweesh, Manar Abdulbaki, John Apostolidis, Salman Al Harbi
Publikováno v:
Biology of Blood and Marrow Transplantation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d14eb9c11d5cdc0a59ddb032243a39cf
http://europepmc.org/articles/PMC7128922
http://europepmc.org/articles/PMC7128922